4HG0.F Qlife Holding AB (publ)
- Market cap
- EUR 1.86M
- P/E
- -
- P/B
- 7.11x
- ROE
- -845.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4HG0.F undervalued?
Graham numberThe Graham number of Qlife Holding AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qlife Holding AB (publ) fundamental analysis
No fundamental analysis for Qlife Holding AB (publ) yet.
Qlife Holding AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qlife Holding AB (publ)
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Qlife Holding AB (publ) was incorporated in 2019 and is based in Gothenburg, Sweden.
Full company profileQlife Holding AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qlife Holding AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 39.6M | 18.0M | 244K | 50.0K | 324K | 1.50M |
| Gross Profit | 19.0M | 35.9M | 14.6M | -158K | -670K | 1.36M |
| Operating Income | -43.9M | -95.7M | -77.1M | -12.9M | -19.4M | -21.7M |
| EBITDA | - | -78.0M | -122M | -36.9M | -18.3M | -20.4M |
| Net Income | -38.8M | -93.1M | -157M | -55.9M | -20.6M | -22.4M |
| EPS | -702 | -1,283 | -298 | -7.79 | -1.30 | -0.78 |
| Balance Sheet | ||||||
| Total Assets | 164M | 193M | 39.0M | 11.7M | 9.63M | 12.6M |
| Total Liabilities | 31.5M | 102M | 62.2M | 13.1M | 17.1M | 9.91M |
| Shareholders' Equity | 132M | 91.1M | -23.1M | -1.41M | -7.51M | 2.65M |
| Cash & Short-term Investments | 73.5M | 14.5M | 1.66M | 2.72M | 1.42M | 4.36M |
| Cash Flow | ||||||
| Operating Cash Flow | -26.7M | -47.7M | -41.8M | -55.9M | -21.5M | -23.7M |
| Capital Expenditure | 26.8M | 42.9M | 20.2M | 16.8M | 0.00 | 0.00 |
| Free Cash Flow | -53.4M | -90.7M | -62.0M | -55.9M | -21.5M | -23.7M |
| Ratios | ||||||
| ROE | -29.3% | -102.2% | - | - | - | -845.5% |
| ROA | -23.7% | -48.3% | -402.0% | -479.9% | -213.4% | -178.4% |
| Net Profit Margin | -97.9% | -517.7% | -64,326.2% | -111,838.0% | -6,345.1% | -1,495.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Qlife Holding AB (publ) dividends
Qlife Holding AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:2000 on Jul 30, 2024.
Who owns Qlife Holding AB (publ)
Ownership data of Qlife Holding AB (publ) is not available yet.
Qlife Holding AB (publ) company profile
- Company name
- Qlife Holding AB (publ)
- Ticker
- 4HG0.F
- ISIN
- SE0022574331
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 2
- Fiscal year end
- December
- Address
- Ullevigatan 19, Gothenburg, Sweden, 411 40
- Website
- qlifeholding.com
About Qlife Holding AB (publ)
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Qlife Holding AB (publ) was incorporated in 2019 and is based in Gothenburg, Sweden.
Qlife Holding AB (publ) management
3- Mr. Thomas WarthoeCo-Founder & CEO · born 1967
- Mr. Lars BangsgaardCo-Founder & CFO · born 1953
- Mr. Peter WarthoeCo-Founder & Chief Scientific Officer · born 1967